NEW HAVEN, Conn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of a new version of its Bloodhound MPN (Myeloproliferative ...

Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

MPN-U patients exhibit lower platelet counts and higher venous thrombosis rates compared to ET, with thrombosis often occurring at atypical sites. Genetic analysis shows JAK2 mutations are more common ...

Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms. MDS is a group of heterogeneous clonal ...

By: Dr. Amrit Kaur Kaler For patients diagnosed with blood cancers such as leukemia, lymphoma, and multiple myeloma, the ...

Chronic myeloid leukaemia (CML) is a paradigmatic clonal disorder primarily driven by the BCR-ABL translocation, which produces a constitutively active tyrosine kinase. Traditionally, this genetic ...

BOZEMAN, MONTANA, USA, February 1, 2024 /EINPresswire.com/ -- Alercell, Inc., an innovative leader in molecular diagnostics, has recently unveiled its latest ...

Think of the bone marrow as the body’s factory for blood and immune cells. In myelodysplastic syndromes (MDS), that factory breaks down—producing too few cells, and the ones that do roll off the line ...